Quick Answer: On November 20, 2026, Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas, announced a voluntary nationwide, consumer-level recall of compounded sterile injections that are still within their beyond-use dates, and the FDA posted the notice the same day. The reason is a potential lack of sterility assurance, a concern that arose after an FDA inspection. The products were dispensed August 10 to September 21, 2026, some through another pharmacy, Clove Rx. When we reviewed the pharmacy’s lot table on November 22, it held 261 entries (247 distinct lot numbers): 82 compounded semaglutide and 121 compounded tirzepatide entries, plus 58 entries for 24 other injections, among them BPC-157 blends, TB-500, GHK-Cu, CJC-1295/ipamorelin, tesamorelin, MOTS-c, NAD+ and glutathione. Greenwich Rx says it has found no contamination and has no reports of adverse events. If your vial’s product, lot and beyond-use date match the list, stop using it and discard it, and call your prescriber about a replacement plan.
The Recall at a Glance
| Item | Detail |
|---|---|
| Company | Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas; some products were compounded for Clove Rx |
| Announced | November 20, 2026 (company notice and FDA posting, same day) |
| Reason | Potential lack of sterility assurance, identified after an FDA inspection and the pharmacy’s own review |
| Dispensed | Nationwide, August 10 to September 21, 2026 |
| Scope | Specific lots still within their beyond-use dates; 261 lot entries on the pharmacy’s list (247 distinct lot numbers, 14 listed under both pharmacies) |
| Beyond-use dates on the list | November 18 to December 22, 2026 |
| Contamination found? | None identified, per Greenwich Rx; the recall is precautionary |
| Adverse events reported? | None reported to Greenwich Rx as of November 20 |
| What to do | Stop using, discard, contact your prescriber; questions to Sedgwick at 888-243-5547 or GreenwichRx6588@sedgwick.com (weekdays, 8 a.m.–5 p.m. ET) |
What Is on the List
The FDA posting links to a filterable table on the Greenwich Rx website that lists every recalled lot by product, strength, package size, lot number, beyond-use date and dispensing pharmacy. We tallied it by product on November 22, 2026. Counts are lot entries, not vials or patients. The pharmacy has not published how many units or customers are involved.
| Product group | Lot entries | Strengths / package |
|---|---|---|
| Tirzepatide with B12, glycine, methylcobalamin or L-carnitine | 121 (16 via Clove Rx) | 5 to 30 mg/mL tirzepatide; 2 mL vials |
| Semaglutide with B12, glycine or methylcobalamin | 82 (11 via Clove Rx) | 1 to 10 mg/mL semaglutide; 1 mL vials |
| BPC-157 alone or blended with TB-500, GHK-Cu and/or KPV | 15 | 3 mg/mL BPC-157 in each; 5 mL |
| Growth-hormone-axis peptides: tesamorelin, tesamorelin/ipamorelin, CJC-1295/ipamorelin, sermorelin, MOTS-c/tesamorelin | 15 | 5 mL |
| GHK-Cu alone or with epithalon/CJC-1295 | 5 | 10 mg/mL GHK-Cu; 5 mL |
| Other peptides: TB-500, MOTS-c, epithalon, thymosin alpha-1, PT-141, DSIP, Semax/Selank, Pinealon/PE 22-28/Selank | 15 | 5 mL |
| NAD+ 100 mg/mL, glutathione 200 mg/mL, Lipo-B and Lipo-C | 8 | 10 mL |
Most of the list is GLP-1 medicine: 203 of the 261 entries, and 27 of the 30 entries marked as dispensed through Clove Rx. Early news coverage focused there. The other 58 entries matter too. They are the injections sold through longevity clinics, med spas and telehealth “peptide” programs, and many people who use them do not think of them as prescription drugs at all.
How to Check Your Vial
- Find the pharmacy on the label. The recall covers products labeled from Greenwich Rx and products received through Clove Rx that Greenwich compounded. If your vial came from Clove Rx, Greenwich asks you to check the list even if you never got a recall letter. It is mailing notices only to its own customers.
- Match three things: the product name and strength, the lot number (formatted like 0006-081026-1) and the beyond-use date. All three appear on the pharmacy label.
- Use the pharmacy’s table. On the Greenwich Rx recall page, filter by product and by dispensing pharmacy. Lot numbers can differ only in the last digit, so check every character.
- Still unsure? Contact Sedgwick, Greenwich Rx’s recall handler, at 888-243-5547 or GreenwichRx6588@sedgwick.com, Monday to Friday, 8 a.m. to 5 p.m. Eastern.
If the beyond-use date has already passed: many of the listed dates fall in late November, so some recalled vials are now past their date. That does not make them safe to keep using. The recall instruction is the same: stop using the vial and discard it.
Why “Sterility Assurance” Matters for Injections
A tablet does not need to be sterile, but anything injected under the skin does. “Lack of sterility assurance” means the pharmacy cannot show that its processes reliably kept the product free of microbes. It does not mean contamination was found, and Greenwich Rx says none was. The risk statement explains why the pharmacy is acting anyway: using a drug that is meant to be sterile but is not “could result in serious infections, which may be life threatening.”
Two features of these products raise the stakes. First, compounded GLP-1s are typically self-injected from multiple-dose vials over weeks. FDA generally recommends discarding a multiple-dose vial of sterile medication within 28 days of first use, even if medication is left and even if the compounder’s instructions allow longer, and always using a new sterile needle and syringe for each dose. Second, injectable GLP-1s need refrigeration. FDA says not to use one that arrives warm or poorly chilled.
Compounded vs FDA-Approved: What’s Different
| FDA-approved (e.g. Wegovy, Zepbound) | 503A compounded injection | |
|---|---|---|
| FDA review before sale | Yes: safety, effectiveness and quality | No. FDA does not verify safety, effectiveness or quality |
| Manufacturing standard | Current good manufacturing practice (CGMP) | Not subject to CGMP; overseen mainly by state boards of pharmacy |
| Adverse-event reporting to FDA | Required for manufacturers | Not required for 503A pharmacies, so problems are likely underreported (FDA) |
| Formulation | Fixed, FDA-reviewed formulation and labeling | Often vials, sometimes with added ingredients such as B12 or glycine |
| When FDA says it is appropriate | Standard option | Only when a patient’s needs cannot be met by an FDA-approved drug |
FDA has collected several warnings specific to compounded semaglutide and tirzepatide. It has received adverse-event reports tied to dosing errors, some requiring hospitalization, when patients or clinicians mismeasured doses drawn from vials. It has received reports of doses beyond the approved labels. It warns about salt forms of semaglutide and about fraudulent products that carry a real pharmacy’s name. As of May 31, 2026, FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide, while noting that causation is often unclear. For how the approved versions compare, see our semaglutide vs tirzepatide guide.
The Peptide Part of the Recall
Several of the non-GLP-1 ingredients on the list have their own history with FDA. On its page of bulk drug substances that may present significant safety risks for compounding, FDA has listed BPC-157, CJC-1295, emideltide (DSIP), epitalon, injectable GHK-Cu, KPV and MOTs-C among substances “nominated but withdrawn” from its category 2 list. Ipamorelin remains in category 2 for 503B outsourcing facilities. Selank, Semax, thymosin alpha-1 and TB-500 (a thymosin beta-4 fragment) also appear on that page. The concerns FDA lists are similar from entry to entry: possible immunogenicity (an immune reaction to the peptide), peptide-related impurities, and little or no human safety data for the proposed routes of administration.
That context is not a finding about any Greenwich Rx vial. It does explain why a sterility problem at a pharmacy making these products deserves attention. For most of these peptides the evidence of benefit in people is already thin, as our BPC-157 evidence guide explains. A recall like this adds a second question: whether the vial itself was sterile. NAD+ and glutathione are better-known molecules, but the recalled products are injections, not capsules. Our NAC vs glutathione comparison covers the oral options.
What to Do If You Have a Recalled Vial
- Stop using it. Do not finish the vial “since it’s almost gone.”
- Discard it safely. Greenwich Rx points to FDA’s guidance on disposing of unused medicines. Put used needles in a sharps container, not loose in the trash.
- Call your prescriber before your next dose. If you are on a GLP-1, ask how to restart or bridge. After a gap, your prescriber may not want you to resume at the same dose. Do not improvise a new dose from a different vial or brand.
- Watch for problems and report them. Contact your clinician if you have experienced anything you think may be related to a recalled product. Problems can also be reported to FDA MedWatch.
- Ask about refunds through the seller. The recall notice does not describe a refund process. Ask Sedgwick, Clove Rx or the telehealth service that prescribed the product.
Get care promptly if an injection site becomes increasingly red, hot, swollen or painful, or if you develop a fever or feel unwell after injecting. Tell the clinician which product and lot you used.
Who Should Do What
- You get compounded semaglutide or tirzepatide by mail: check the label for Greenwich Rx or Clove Rx today, even if you think your provider uses a different pharmacy. Telehealth customers often do not know which pharmacy compounds their medicine, a point FDA makes in its compounding Q&A.
- You use peptide or NAD+ injections from a clinic or med spa: ask the clinic which pharmacy compounded your vials and whether any lots are on the list.
- You are deciding between compounded and brand-name GLP-1s: FDA’s position is that compounded drugs should only be used when an approved drug cannot meet your medical needs. Its telehealth red flags include claims that a compounded drug is “the same as” an approved one, prices that seem too good to be true, and no licensed doctor available for questions.
- You prescribe or dispense these products: the notice asks clinics that hold recalled product to stop use and discard it as well.
Frequently Asked Questions
What did Greenwich Rx recall?
Specific lots of compounded sterile injections still within their beyond-use dates, dispensed nationwide from August 10 to September 21, 2026. The pharmacy's list has 261 lot entries: 82 compounded semaglutide, 121 compounded tirzepatide, and 58 for other injections such as BPC-157, TB-500, GHK-Cu, tesamorelin, NAD+ and glutathione.
Why were the Greenwich Rx products recalled?
For a potential lack of sterility assurance, a concern that arose after an FDA inspection of the pharmacy and its own review. Greenwich Rx says it has not found contamination and has not received reports of adverse events, and calls the recall precautionary.
I got my semaglutide or tirzepatide from Clove Rx. Am I affected?
Possibly. Greenwich Rx compounded some products for Clove Rx, and 30 entries on the list are marked as dispensed through Clove Rx, 27 of them GLP-1 products. Greenwich says Clove Rx customers should check the list even if they did not receive a recall letter.
How do I check whether my vial is recalled?
Compare the product name and strength, lot number and beyond-use date on your label with the table on the Greenwich Rx recall page, filtering by product and dispensing pharmacy. For help, contact Sedgwick at 888-243-5547 or GreenwichRx6588@sedgwick.com, weekdays 8 a.m. to 5 p.m. Eastern.
What should I do with a recalled vial?
Stop using it and discard it, following FDA's guidance on disposing of unused medicines and putting needles in a sharps container. Contact your prescriber before your next dose, and tell a clinician about any problems you think may be related.
Has anyone been hurt by the recalled products?
Greenwich Rx said on November 20, 2026 that it had not received any reports of adverse events related to the recall. The risk is that a non-sterile injectable could cause serious, potentially life-threatening infections.
Are compounded semaglutide and tirzepatide FDA-approved?
No. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are sold. FDA says they should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Sources
- FDA (company announcement): Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Sterile Products Due to Lack of Sterility Assurance. November 20, 2026
- Greenwich Rx: recall notice and full list of affected products, lots and beyond-use dates (accessed November 22, 2026)
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (multiple-dose vials, storage, dosing errors, adverse-event counts as of May 31, 2026)
- FDA: Compounding and the FDA: Questions and Answers
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 and withdrawn nominations)
- FDA: Disposal of Unused Medicines: What You Should Know
- FDA: MedWatch Safety Information and Adverse Event Reporting Program
- FDA: BeSafeRx, Your Source for Online Pharmacy Information
Medical disclaimer: This article is for educational purposes and does not replace medical advice. Consult a licensed healthcare provider before starting any supplement, medication, or treatment — particularly if you are pregnant, breastfeeding, taking other medications, or have a diagnosed medical condition.